Lactose (India) Peer Comparison

BSE: 524202

₹105.35

₹1.25 (1.20%)

As on 05-Nov-2026IST

Market cap

₹133 Cr

Revenue (TTM)

₹171 Cr

P/E Ratio

19.1

P/B Ratio

2

Div. Yield

0 %

Edit

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Market cap (₹ Cr)	133	30,838	31,793	32,345	28,809
Revenue (₹ Cr)	171	1,593	9,779	3,751	1,936
Net Profit (₹ Cr)	6.93	438.64	-270.51	405.00	288.22
Net Margin (%)	4.02	27.16	-2.71	10.48	14.79
RoE (%)	10.89	25.02	-2.55	7.91	29.77
Price to Earnings	19.14	70.22	--	78.89	99.96
Price-To-Book	1.97	16.60	3.90	6.27	21.46

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Operating Revenue	170.68	1,592.52	9,778.62	3,751.00	1,935.80
Total Income	172.46	1,615.23	9,993.26	3,863.00	1,948.58
Total Expenditure	151.26	969.32	8,578.44	2,984.00	1,485.56
EBITDA	19.42	623.20	1,200.18	767.00	450.24
Depreciation	6.01	41.96	887.82	228.00	50.83
EBIT	13.41	581.24	312.36	539.00	399.41
Interest	5.63	4.21	347.94	218.00	40.84
Other Income	1.78	22.71	214.64	112.00	12.78
Exceptional Items	0.00	0.00	-216.88	12.00	0.00
Profit before Tax	9.56	599.74	-37.82	445.00	371.35
Provision for Tax	2.64	161.10	232.69	40.00	83.14
Profit after Tax	6.93	438.64	-270.51	405.00	288.22

Liabilities (₹ Cr)

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Shareholder's Funds	64.79	1,857.45	8,142.24	5,158.00	1,288.82
Minority Interest	0.00	0.51	0.55	5.00	0.00
Non-Current Liabilities	28.64	47.15	5,213.99	1,617.00	202.03
Current Liabilities	89.80	253.37	5,158.51	1,785.00	835.87
Total Liabilities	183.23	1,983.96	17,723.32	8,578.00	2,326.71

Assets (₹ Cr)

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Non-Current Assets	68.58	1,132.12	10,687.30	5,527.00	519.60
Current Assets	98.62	1,012.00	7,253.65	2,764.00	1,681.81
Total Assets	183.23	1,983.96	17,723.32	8,578.00	2,326.71
Total Debt*	61.68	26.49	5,495.48	2,125.00	259.37
Net Current Assets	8.82	758.64	2,095.14	979.00	845.94
Contingent Liabilities	12.92	17.25	95.72	768.26	19.09

Cashflow (₹ Cr)

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Cash From Operating Activities	5.56	292.17	1,652.60	390.00	205.05
Cash Flow from Investing Activities	-10.22	-265.94	-826.03	-241.00	-409.72
Cash from Financing Activities	0.71	4.10	-38.98	-54.00	283.07
Net Cash Inflow / Outflow	-3.95	30.33	787.59	95.00	78.39

Ratios

Profitability Ratios

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
ROCE (%)	11.35	32.42	1.24	6.79	29.22
ROE (%)	10.89	25.02	-2.55	7.91	29.77
ROA (%)	4.38	22.40	-1.56	4.65	24.77
EBIT Margin (%)	7.86	36.50	3.19	14.37	20.63
Net Margin (%)	4.02	27.16	-2.71	10.48	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Revenue Growth (%)	34.91	45.18	9.43	25.70	46.65
EBIT Growth (%)	28.97	115.51	-3.72	139.56	62.13
Net Profit Growth (%)	57.67	95.80	-199.34	894.12	89.49
EPS Growth (%)	57.67	63.29	-410.28	599.72	78.60
Book Value Growth (%)	11.59	26.03	0.33	13.47	144.31

Valuation Ratios

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Price / Earnings	19.14	70.22	-152.88	80.96	98.42
Price / Book Value	1.97	16.60	3.90	6.27	21.46
Dividend Yield (%)	0.00	0.07	0.00	0.00	0.09
EV/EBITDA	9.97	49.16	29.94	44.08	63.79
Market Cap (₹ Cr)	101.22	20,944.75	18,108.89	19,071.62	12,753.19

Solvency Ratios

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Debt to Equity	0.35	0.02	0.55	0.28	0.11
Short term debt to equity ratio	0.46	0.00	0.09	0.09	0.05
Current Ratio	1.10	3.99	1.41	1.55	2.01
Quick Ratio	0.48	2.89	0.77	1.00	1.14
Interest Coverage	2.70	143.52	0.89	3.04	10.09

Operating Efficiency Ratios

	Lactose (India)	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Debtors to sales (%)	19.60	22.50	23.05	16.85	26.28
Asset Turnover	1.08	0.81	0.56	0.43	1.66
Receivable days	61.58	88.98	78.20	58.75	40.13
Inventory Days	89.97	56.04	93.30	75.82	60.29
Payable days	94.73	99.95	226.14	186.21	232.47
Cash Conversion Cycle	56.82	45.07	-54.64	-51.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly